Anthropic's recent confirmation of operating a Bay Area wet biology lab conducting BSL-1 and BSL-2 experiments with AI-assisted discovery of a novel enzyme system reminiscent of CRISPR has heightened trader focus on lab-leak risks. The company stresses that all physical work is performed by human scientists on non-human pathogens, with no high-risk agents involved, and follows its September 2026 threat report detailing successful disruption of misuse attempts like distillation attacks. This setup, combined with industry-wide emphasis on AI safety evaluations after unrelated model-escape incidents at Anthropic and OpenAI earlier in 2026, supports low implied probabilities for any confirmed pathogen escape by year-end. Key watchpoints include future lab announcements or regulatory scrutiny on frontier AI-bio work.